48 related articles for article (PubMed ID: 16304122)
1. Adjunctive abciximab improves patency and functional outcome in endovascular treatment of femoropopliteal occlusions: initial experience.
Dörffler-Melly J; Mahler F; Do DD; Triller J; Baumgartner I
Radiology; 2005 Dec; 237(3):1103-9. PubMed ID: 16304122
[TBL] [Abstract][Full Text] [Related]
2. Single center experience with provisional abciximab therapy in complex lower limb interventions.
Keo H; Diehm N; Baumgartner R; Husmann M; Baumgartner I
Vasa; 2008 Aug; 37(3):257-64. PubMed ID: 18690593
[TBL] [Abstract][Full Text] [Related]
3. Use of abciximab during infrainguinal peripheral vascular interventions: initial experience.
Stavropoulos SW; Solomon JA; Soulen MC; Clark TW; Shlansky-Goldberg RD
Radiology; 2003 Jun; 227(3):657-61. PubMed ID: 12773673
[TBL] [Abstract][Full Text] [Related]
4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
5. Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: a randomized trial.
Ansel GM; Silver MJ; Botti CF; Rocha-Singh K; Bates MC; Rosenfield K; Schainfeld RM; Laster SB; Zander C
Catheter Cardiovasc Interv; 2006 Feb; 67(2):288-97. PubMed ID: 16408299
[TBL] [Abstract][Full Text] [Related]
6. Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis--APART trial.
Tepe G; Hopfenzitz C; Dietz K; Wiskirchen J; Heller S; Ouriel K; Ziemer G; Claussen CD; Duda SH
Radiology; 2006 Jun; 239(3):892-900. PubMed ID: 16641342
[TBL] [Abstract][Full Text] [Related]
7. Vascular brachytherapy with 192Ir after femoropopliteal stent implantation in high-risk patients: twelve-month follow-up results from the Vienna-5 trial.
Wolfram RM; Budinsky AC; Pokrajac B; Pötter R; Minar E
Radiology; 2005 Jul; 236(1):343-51. PubMed ID: 15987985
[TBL] [Abstract][Full Text] [Related]
8. Results of second-time angioplasty and stenting for femoropopliteal occlusive disease and factors affecting outcomes.
Robinson WP; Nguyen LL; Bafford R; Belkin M
J Vasc Surg; 2011 Mar; 53(3):651-7. PubMed ID: 21129908
[TBL] [Abstract][Full Text] [Related]
9. [Factors determining late patency of aortobifemoral bypass graft].
Davidović LB; Lotina SI; Kostić DM; Cinara II; Cvetković SD; Stojanov PL; Velimirović DB; Marković MM; Pejkić SA; Vukotić AM
Srp Arh Celok Lek; 1997; 125(1-2):24-35. PubMed ID: 17974352
[TBL] [Abstract][Full Text] [Related]
10. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five-year follow-up--prospective randomized study.
Wolfram RM; Budinsky AC; Pokrajac B; Potter R; Minar E
Radiology; 2006 Sep; 240(3):878-84. PubMed ID: 16926331
[TBL] [Abstract][Full Text] [Related]
11. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
12. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Adjunctive Intra-Arterial Abciximab in the Management of Acute Limb Ischemia.
Salzler GG; Graham A; Connolly PH; Schneider DB; Meltzer AJ
Ann Vasc Surg; 2016 Jan; 30():66-71. PubMed ID: 26476269
[TBL] [Abstract][Full Text] [Related]
14. Late outcomes of balloon angioplasty and angioplasty with selective stenting for superficial femoral-popliteal disease are equivalent.
Nguyen BN; Conrad MF; Guest JM; Hackney L; Patel VI; Kwolek CJ; Cambria RP
J Vasc Surg; 2011 Oct; 54(4):1051-1057.e1. PubMed ID: 21636240
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
16. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
17. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study.
Admiral Investigators
Eur Heart J; 2005 Dec; 26(23):2520-3. PubMed ID: 16249219
[TBL] [Abstract][Full Text] [Related]
18. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
[TBL] [Abstract][Full Text] [Related]
20. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis.
Schweizer J; Kirch W; Koch R; Müller A; Hellner G; Forkmann L
Angiology; 2000 Nov; 51(11):913-23. PubMed ID: 11103860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
